Antral gastritis Medical Services in China

Antral gastritis is a localized form of chronic gastritis characterized by inflammation predominantly confined to the gastric antrum—the lower third of the stomach that connects to the pylorus and regulates gastric emptying. Unlike pangastritis or fundic-predominant gastritis, antral gastritis spares the acid-producing fundus and corpus in early stages, preserving basal acid secretion while often disrupting gastrin regulation and mucosal defense mechanisms. Pathogenesis centers on persistent mucosal injury from Helicobacter pylori infection—present in over 80% of cases—triggering chronic neutrophilic and lymphocytic infiltration, oxidative stress, and progressive glandular atrophy. Other contributors include long-term NSAID use, bile reflux (especially post-cholecystectomy or with impaired pyloric function), autoimmune mechanisms (less common than in corpus-predominant disease), and lifestyle factors such as smoking, heavy alcohol consumption, and chronic psychological stress. Epidemiologically, antral gastritis affects an estimated 30–50% of adults globally, with higher prevalence in low- and middle-income countries due to endemic H. pylori transmission. In China, seroprevalence exceeds 55% in adults over age 40, and antral-predominant patterns account for ~60% of biopsy-confirmed chronic gastritis cases. Risk factors include age >45 years, rural residence, crowded living conditions during childhood, untreated H. pylori infection, habitual NSAID or aspirin use, and comorbidities like type 2 diabetes and metabolic syndrome. While often asymptomatic in early stages, patients commonly report epigastric discomfort, early satiety, postprandial bloating, nausea, and intermittent dull pain—symptoms frequently mistaken for functional dyspepsia. Untreated, antral gastritis may progress to atrophic gastritis, intestinal metaplasia, and—over decades—elevate gastric cancer risk, particularly when combined with H. pylori virulence factors (CagA+/VacA+ strains) and host genetic susceptibility (e.g., IL-1β polymorphisms). Quality of life impact is substantial: patients report reduced work productivity, dietary restrictions (e.g., avoidance of spicy, acidic, or fatty foods), sleep disruption due to nocturnal discomfort, and heightened anxiety about malignancy—especially following endoscopic diagnosis with biopsy findings of metaplasia or dysplasia. Psychological burden is underrecognized; studies show 25–35% of patients meet criteria for health-related anxiety or mild depression linked to symptom chronicity and diagnostic uncertainty. Early diagnosis via high-definition upper endoscopy with targeted antral biopsies—and confirmation of H. pylori status via rapid urease test, histology, or stool antigen assay—is critical. Management focuses not only on symptom relief but also on mucosal healing, eradication of modifiable drivers, and surveillance stratification based on histopathological severity (e.g., OLGA/OLGIM staging).

Antral gastritis refers to chronic inflammation localized predominantly to the gastric antrum—the distal portion of the stomach that connects to the pylorus and duodenum. It is commonly associated with Helicobacter pylori (H. pylori) infection, long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), bile reflux, autoimmune phenomena, or lifestyle-related factors such as excessive alcohol intake, smoking, and chronic stress. Diagnosis typically relies on upper gastrointestinal endoscopy with targeted biopsies, histopathological assessment (including evaluation for intestinal metaplasia, atrophy, or dysplasia), and confirmatory testing for H. pylori (e.g., rapid urease test, stool antigen assay, or PCR-based detection). Given its multifactorial etiology and variable clinical presentation—from asymptomatic mucosal changes to epigastric discomfort, early satiety, nausea, or iron-deficiency anemia—management must be individualized, evidence-based, and stratified by severity, etiology, and risk for complications.

Conservative treatment forms the cornerstone of management for most patients with mild-to-moderate antral gastritis. This includes strict dietary modification: avoidance of irritants such as spicy foods, caffeine, carbonated beverages, and highly acidic or fried items; adoption of small, frequent meals to reduce gastric distension and acid exposure; and elimination of alcohol and tobacco, both of which impair mucosal defense mechanisms and delay healing. Stress reduction techniques—including cognitive behavioral therapy, mindfulness-based stress reduction, and regular physical activity—are recommended adjuncts, given the well-documented bidirectional relationship between psychological stress and gastric mucosal integrity. Patients are also advised to discontinue NSAIDs when clinically feasible; if analgesia remains necessary, acetaminophen or COX-2 selective inhibitors (with concurrent proton pump inhibitor [PPI] coverage) may be considered under gastroenterologist supervision.

Pharmacologic therapy is tailored to the underlying cause. For H. pylori–positive cases, first-line eradication regimens follow international consensus guidelines (e.g., Toronto Consensus, ACG Clinical Guideline) and local antimicrobial resistance patterns. In China, where clarithromycin resistance exceeds 25%, bismuth-containing quadruple therapy (PPI + bismuth subsalicylate + tetracycline + metronidazole) for 10–14 days is preferred over standard triple therapy. High-dose dual therapy (esomeprazole 40 mg three times daily + amoxicillin 1 g three times daily) is increasingly utilized in regions with documented high-amoxicillin susceptibility. All regimens require post-treatment confirmation of eradication via urea breath test or stool antigen test at least four weeks after therapy completion. For H. pylori–negative, NSAID-induced, or reflux-associated antral gastritis, acid suppression remains central: PPIs (e.g., omeprazole 20 mg, esomeprazole 40 mg, or rabeprazole 20 mg once daily) are administered for 4–8 weeks, followed by step-down or on-demand dosing based on symptom control and endoscopic reassessment. In cases of bile reflux gastritis, ursodeoxycholic acid (13–15 mg/kg/day) or bile acid sequestrants (e.g., cholestyramine) may be trialed, though evidence remains limited. Mucosal protectants—including rebamipide (100 mg three times daily) and teprenone (50 mg three times daily)—are widely used in Asia to enhance prostaglandin synthesis, stimulate mucus/bicarbonate secretion, and promote epithelial restitution; these agents are particularly beneficial in chronic atrophic antral gastritis with impaired mucosal repair capacity.

Surgical intervention is exceedingly rare in isolated antral gastritis and is reserved only for refractory, complication-driven scenarios. Indications include severe, medically unresponsive bleeding from erosive antral lesions (e.g., Dieulafoy lesion confined to the antrum), gastric outlet obstruction secondary to fibrotic antral stenosis (often in longstanding autoimmune or granulomatous gastritis), or suspicion of malignancy in the context of high-grade dysplasia or early gastric adenocarcinoma arising within chronically inflamed antral mucosa. Laparoscopic antrectomy or partial gastrectomy may be performed in select centers, but endoscopic resection (e.g., endoscopic submucosal dissection) is preferred for localized neoplastic lesions. Surgery is never indicated for routine inflammatory changes and carries risks including dumping syndrome, nutritional deficiencies (especially vitamin B12, iron, calcium), and postgastrectomy syndromes—thus requiring rigorous preoperative risk-benefit analysis and multidisciplinary input.

Treatment in China offers several distinct advantages. First, China’s national endoscopy infrastructure supports widespread access to high-definition magnifying endoscopy with narrow-band imaging (NBI) and linked-color imaging (LCI), enabling real-time differentiation of gastritis subtypes and early neoplastic changes. Second, integrated H. pylori resistance surveillance networks (e.g., the China Antimicrobial Resistance Surveillance Network) inform regional guideline adaptations, improving eradication success rates (>90% in tertiary centers using culture-guided or molecular resistance testing). Third, traditional Chinese medicine (TCM) is systematically incorporated into integrative protocols: formulas such as Weikangning decoction or Huangqin Tang—standardized for quality and pharmacokinetics—demonstrate anti-inflammatory, antioxidant, and H. pylori–inhibitory effects in randomized controlled trials, and are approved by the National Medical Products Administration (NMPA) as adjunctive therapy. Fourth, China’s tiered healthcare system facilitates seamless referral from community clinics to specialized digestive disease hospitals, ensuring timely access to advanced diagnostics (e.g., serum pepsinogen I/II ratio, gastrin-17 assays for atrophic gastritis staging) and longitudinal monitoring.

Recovery advice emphasizes sustained mucosal healing and prevention of recurrence. Patients should undergo repeat endoscopy at 6–12 months if initial biopsy revealed atrophy, intestinal metaplasia, or persistent H. pylori infection despite therapy. Lifestyle adherence must continue indefinitely: strict avoidance of NSAIDs without gastroprotection, moderation of alcohol, and maintenance of a low-inflammatory diet rich in antioxidants (e.g., cruciferous vegetables, berries, green tea). Vitamin supplementation—particularly vitamin B12 (intramuscular or high-dose oral), iron, and folate—is recommended for patients with confirmed atrophic gastritis and hypochlorhydria. Regular follow-up with a gastroenterologist every 6–12 months is advised for those with premalignant changes, incorporating serologic biomarkers and risk-stratified surveillance intervals per the Updated Sydney System and Asian Pacific Guidelines. Finally, patient education regarding symptom recognition (e.g., new-onset anemia, weight loss, persistent vomiting) and prompt reporting is critical to mitigate progression to gastric cancer—a known sequela of untreated chronic antral gastritis, especially in high-risk populations.